CN111035017A - 一种防治肌肉流失的口服液 - Google Patents
一种防治肌肉流失的口服液 Download PDFInfo
- Publication number
- CN111035017A CN111035017A CN201911271940.3A CN201911271940A CN111035017A CN 111035017 A CN111035017 A CN 111035017A CN 201911271940 A CN201911271940 A CN 201911271940A CN 111035017 A CN111035017 A CN 111035017A
- Authority
- CN
- China
- Prior art keywords
- muscle
- oral liquid
- vitamin
- protein
- glutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 63
- 239000007788 liquid Substances 0.000 title claims abstract description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 29
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 29
- 235000021119 whey protein Nutrition 0.000 claims abstract description 28
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 244000068988 Glycine max Species 0.000 claims abstract description 26
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims abstract description 25
- 108010044940 alanylglutamine Proteins 0.000 claims abstract description 25
- 229960002648 alanylglutamine Drugs 0.000 claims abstract description 25
- 239000011575 calcium Substances 0.000 claims abstract description 25
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 25
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 claims abstract description 22
- PWLNAUNEAKQYLH-UHFFFAOYSA-N butyric acid octyl ester Natural products CCCCCCCCOC(=O)CCC PWLNAUNEAKQYLH-UHFFFAOYSA-N 0.000 claims abstract description 22
- UUIQMZJEGPQKFD-UHFFFAOYSA-N n-butyric acid methyl ester Natural products CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000008367 deionised water Substances 0.000 claims abstract description 18
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 18
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 17
- 235000021323 fish oil Nutrition 0.000 claims abstract description 15
- 239000011647 vitamin D3 Substances 0.000 claims description 6
- 239000011653 vitamin D2 Substances 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 abstract description 17
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 17
- 235000019166 vitamin D Nutrition 0.000 abstract description 17
- 239000011710 vitamin D Substances 0.000 abstract description 17
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 17
- 229940046008 vitamin d Drugs 0.000 abstract description 17
- 208000001076 sarcopenia Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000014674 injury Diseases 0.000 abstract description 10
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 230000008733 trauma Effects 0.000 abstract description 8
- 230000007774 longterm Effects 0.000 abstract description 6
- 201000008827 tuberculosis Diseases 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 238000003756 stirring Methods 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 24
- 235000016709 nutrition Nutrition 0.000 description 21
- 230000001954 sterilising effect Effects 0.000 description 21
- 230000035764 nutrition Effects 0.000 description 20
- 235000013305 food Nutrition 0.000 description 17
- 239000002994 raw material Substances 0.000 description 17
- 102000008934 Muscle Proteins Human genes 0.000 description 16
- 108010074084 Muscle Proteins Proteins 0.000 description 16
- 239000000839 emulsion Substances 0.000 description 16
- 238000002156 mixing Methods 0.000 description 15
- 210000002027 skeletal muscle Anatomy 0.000 description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- 230000014616 translation Effects 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 238000001243 protein synthesis Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000005693 branched-chain amino acids Chemical class 0.000 description 9
- 210000000663 muscle cell Anatomy 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 210000004347 intestinal mucosa Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000001087 myotubule Anatomy 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 238000009924 canning Methods 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 108010073771 Soybean Proteins Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 239000004376 Sucralose Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- -1 compound amino acids Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000019408 sucralose Nutrition 0.000 description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000007686 potassium Nutrition 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 102000009310 vitamin D receptors Human genes 0.000 description 3
- 108050000156 vitamin D receptors Proteins 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 2
- 229960005164 acesulfame Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000003365 myofibril Anatomy 0.000 description 2
- 235000006286 nutrient intake Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000001705 insufficient nutrition Nutrition 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种防治肌肉流失的口服液,每100ml包含:丙氨酰谷氨酰胺5‑20g、大豆肽4‑8g、β‑羟基β‑甲基丁酸钙1‑3g、去离子水适量。还可以包含,鱼油6‑10g、磷脂0.8‑1.2g、维生素D2或D315‑25μg;还可以包含,乳清分离蛋白(WPI90)5‑10g;用于肌少症、长期卧床、大手术或创伤人群以及结核、肿瘤等慢性消耗性疾病患者。
Description
技术领域
本发明属于营养与保健食品领域,确切的说涉及一种防治肌肉流失的口服液。
背景技术
人体内的肌肉有三种,即骨骼肌、心肌和平滑肌。心肌存在于心脏,平滑肌存在于内脏与血管,二者运动都不受自主控制、质量在成人中变化也不大。通常所指肌肉不包括心肌与平滑肌,单指骨骼肌。骨骼肌是人体运动系统的重要组成部分,其质量与力量决定着人的运动能力。肌肉由肌细胞集合成束。因肌细胞呈纤维状,所以又称肌纤维。骨骼肌纤维内部存在众多肌原纤维,肌原纤维由肌球蛋白和肌动蛋白两种丝状蛋白质组成,因此蛋白质是骨骼肌的主要组成成分。人体蛋白质50%-75%存在于骨骼肌中,全身每天有1%-2%的肌肉蛋白更新(包含蛋白质的合成和分解)。
所谓肌肉流失,是指一段时间内,肌肉蛋白质分解多于合成,使得肌纤维的质量与大小,处于不断减少过程中。肌肉流失30%即影响其正常功能,出现活动能力下降,易疲劳、身体虚弱,逐渐发展到容易跌倒、骨折,独立生活能力下降甚至长期卧床,增加死亡的危险性。防治肌肉流失,不仅可以增强老年人体质、改善生活自理能力与生存质量,而且可以提高身体免疫力、促进疾病患者康复,降低医疗费用与病死率。
衰老与某些疾病状态下,都会发生肌肉流失。正常生理条件下,50岁以后,随着年龄增长,人体内骨骼肌质量,平均每年减少1%-2%,肌力每年降低1.5%-5%。60岁以上,肌肉流失约为20-30%,80岁以上约丢失50%。某些老年人肌肉量少于所在年龄段人群的肌肉量均值,医学上称为肌肉衰减综合症(Sarcopenia)。肌肉衰减综合症,又叫肌少症,于1989年由美国Tufts大学的Rosenberg首次命名,是与增龄相关的进行性骨骼肌质量减少、伴有肌肉力量与肌肉功能减退的综合征。2010年,欧洲肌肉减少症工作组(European WorkingGroup on Sarcopenia in Older People,EWGSOP)提出了肌少症诊断标准,即测定肌肉质量、肌肉力量和躯体行走能力。据估计,目前我国肌少症的发病率为9.8%(男12.9%,女6.7%)。随着我国进入老龄社会,肌少症人群的数量会越来越大。这一趋势已经引起高层的重视。国家卫计委2013年发布的食品安全国家标准特殊医学用途配方食品通则(GB29922-2013),将肌肉衰减综合症的全营养配方食品列入其中。2015年,中国营养学会老年营养分会、中国营养学会临床营养分会与中华医学会肠外肠内营养学分会老年营养支持学组,就“肌肉衰减综合征营养与运动干预”,达成中国专家共识(营养学报,2015,37(4):320-324.)。
继发性肌肉流失主要见于长期卧床、大手术或创伤病人以及结核、肿瘤等慢性消耗性疾病患者。长期卧床人群食欲不振,进食量少,肠粘膜细胞营养不足,动员肌肉,肌肉分解大于合成,体积、质量变小。此外,长期卧床病人因缺少运动与体能锻炼,导致肌肉流失。大手术、创伤应激增加体内蛋白质的分解消耗,伤口愈合需要摄入更多蛋白质,特别是消化器官手术病人,饮食受限,致蛋白营养摄入不足,动员肌肉。躯干、下肢手术或创伤病人活动受限,致肌肉快速流失。结核、肿瘤等慢性消耗性疾病患者,体内营养被病灶或瘤体消耗,加之药物治疗等因素导致食欲低下、呕吐,食物营养素摄入量严重不足,肠粘膜缺乏营养,不仅降低免疫力,且动员肌肉,肌肉流失随之而来。病理性肌肉流失,除导致身体虚弱、易疲劳、生活自理能力下降外,还伴随伤口愈合与疾病恢复缓慢,身体抵抗力下降,并发症增多。
综上所述,无论肌少症人群,还是长期卧床、大手术或创伤病人以及结核、肿瘤等慢性消耗性疾病患者,发生肌肉流失的原因,要么因衰老、食欲低下或饮食受限等原因,致肠道功能下降,蛋白质供给或吸收不足,要么因活动受限,致肌肉运动不足。因此防治肌肉流失,营养与运动二者缺一不可。
近年来研究发现,肠道功能对人体健康的重要性,无论如何强调都不为过。肠道除了具有食物消化、营养吸收功能以外,还影响人体情绪。肠道还是全身最大的免疫器官——肠粘膜及其分泌物构成了强大的物理、化学与免疫学屏障,与肠道中的正常菌群共同守护人体健康。当食物摄入不足时,不仅会引起全身营养素供给缺乏,也会严重影响肠粘膜的正常功能,导致营养素吸收率下降、肠粘膜通透性增加、肠道细菌移位,甚至肠道毒素入血。这也是近年来国内外格外强调肠内营养的重要原因。
谷氨酰胺是人体内数量最大的游离氨基酸,约占人体游离氨基酸总量的60%,主要存在于血液、肌肉中。人体内谷氨酰胺主要在骨骼肌内合成,所以骨骼肌是谷氨酰胺的生产车间与储存库。作为肠粘膜细胞、免疫细胞的主要能量来源,谷氨酰胺对于修复肠粘膜损伤、维护肠粘膜的完整性、消除肠道炎症、改善吸收功能、恢复与重建肠道屏障功能与免疫功能,都具有重要意义。谷氨酰胺还通过刺激生长激素、胰岛素和睾酮的分泌,促进肌肉蛋白质合成、抑制蛋白分解,使机体处于合成代谢状态。另外,储存于骨骼肌中的谷氨酰胺,还可通过增加肌肉细胞容积,促进肌细胞的生长和分化。大手术、外伤及癌症等疾病与营养不良状态下,机体对谷氨酰胺的需求量远远大于内源性谷氨酰胺的产生量。肌少症人群体内谷氨酰胺消耗严重。当血液中谷氨酰胺耗尽后,就会动用肌肉中的谷氨酰胺,使得肌肉进入的蛋白分解状态,从而引起肌肉流失。口服补充谷氨酰胺,不仅有利于维护肠道健康,还可以防治肌肉流失。另外,肌肉流失患者多属年老体弱人群,身体抵抗力弱,服用谷氨酰胺,可增强免疫力,预防并发症、促进身体康复。因此,防止肌肉流失产品中,添加谷氨酰胺非常必要。
由于蛋白质是肌肉的主要组成成分,所以,以补充蛋白质为目标的乳清蛋白粉、大豆蛋白粉及其混合蛋白粉,成为防治肌肉流失的主流产品。考虑到中老年人的蛋白质消化能力下降(比如胃酸、胃蛋白酶、胰蛋白酶分泌不足,胃肠蠕动减慢),肽类产品,包括胶原蛋白肽、大豆肽、乳清蛋白肽、酪蛋白肽,甚至水解复合氨基酸(如江中药业的初元口服液),也进入了补充蛋白营养的行列。骨骼肌蛋白中含量较高的亮氨酸、异亮氨酸与缬氨酸等支链氨基酸(BCAA),属于人体自身不能合成的必需氨基酸,具有刺激肌肉蛋白质合成的作用,在某些防治肌肉流失的高端产品中也有添加。
尽管蛋白质(包括肽类、必需氨基酸、支链氨基酸甚至谷氨酰胺)是防治肌肉流失的必要营养素,但是蛋白质或氨基酸的作用是有限的。因为构成肌肉的肌纤维是一个完整细胞,其增殖与生长,包括细胞膜的损伤修复,都离不开构成细胞膜的主要原料——磷脂。无论肌纤维增粗还是肌细胞增殖,都需要维生素D等营养素的参与。从发病机理来看,老年或疾病患者体内存在的慢性炎症与氧化反应,也是导致肌肉流失的重要原因。因此,肌肉衰减综合征营养与运动干预中国专家共识(2015)推荐意见指出,除了口服补充富含亮氨酸等支链氨基酸的优质蛋白质、适量运动外,还要补充ω-3多不饱和脂肪酸、维生素D与抗氧化营养素(维生素C、维生素E、类胡萝卜素、硒)。DHA、EPA属人体必需脂肪酸,可以降低炎症反应水平。维生素D除了参与钙磷代谢,还有抗炎、调节免疫与刺激肌肉细胞增殖与生长的作用。维生素C、维生素E与类胡萝卜素等抗氧化剂可以对抗氧化反应。
β-羟基β-甲基丁酸(β-hydroxyβ-methyl butyrate,HMB),是天然存在于人体骨骼肌中的亮氨酸代谢产物,但其作用强度显著高于同当量亮氨酸。近年研究发现,HMB主要通过以下机制影响骨骼肌代谢:1)激活哺乳动物雷帕霉素靶蛋白(mammalian Target OfRapamycin,mTOR,一种蛋白激酶,在控制mRNA翻译效率中起核心作用)信号途径,刺激蛋白质合成;2)抑制泛素蛋白酶体途径(Ubiquitin Proteasome pathway,UPP),减少肌肉蛋白质分解;3)在体内转化为β-羟基β-甲基戊二酰辅酶A(HMG-CoA),促进合成胆固醇,支持快速修复肌肉和免疫系统细胞损伤,维护细胞膜的完整性;4)刺激肌肉卫星细胞,促进肌肉再生;5)增加内质网钙释放。临床研究表明,适量补充HMB,配合抗阻运动,可用于防治肌少症,对提高肌肉质量、增强肌肉力量都有一定作用。大手术、创伤、癌症、长期卧床、能量摄入不足与运动损伤人群,补充HMB,防治肌肉流失效果显著。2011年,我国批准β-羟基β-甲基丁酸钙(HMBCa)为食品新原料,每日食用量≤3克。2017年,又将HMBCa使用范围扩大至饮料、乳及乳制品、可可制品、巧克力及巧克力制品、糖果、烘焙食品、运动营养食品、特殊医学用途配方食品。
纵观国内防治肌肉流失产品专利申请,有以下特点,其一,几乎所有专利产品剂型都是混合粉剂。除CN110226756A所述混合粉经辐照灭菌处理外,其余均为简单混合粉,达不到完全无菌要求。由于粉剂产品不是完全无菌产品,而产品目标人群均为年老体弱群体,加之用温水自行冲服,渗透压不易控制,服用后极易引起腹泻、腹胀等胃肠道不适。
其二、部分专利产品使用药食同源中药材,与大豆蛋白或乳清蛋白(包括肽、支链氨基酸等)、复合维生素、复合矿物质等混合,制成粉剂。如CN103416760B、CN109349622A使用了薏苡仁、酸枣仁、杏仁等;CN104187634A与CN104996992A使用石斛、虫草菌丝体与蛹虫草、灵芝及其孢子粉、五味子、菟丝子、当归、熟地、龟版、黄芪、白术、车前子、白芍、枣仁、砂仁、人参等;CN107927797A与CN108095072A使用牛膝、黄芪、白术、熟地等;CN109588709A使用了火麻仁蛋白。这类产品存在两个问题;首先,无论中药材细粉,还是提取物口味都不佳,致产品口感与口味较差。其次,因药食同源中药材起效剂量大,致使产品服用量大大增加。对于原本食欲不佳的老年、卧床、消耗性疾病患者以及手术、创伤饮食受限人群,难以坚持服用,效果大打折扣。
其三,添加谷氨酰胺的医用营养食品少,运动营养食品多。如前所述,肌肉流失人群年老体弱,且体内谷氨酰胺消耗巨大,所以防治肌肉流失产品中添加谷氨酰胺,是非常必要的。经检索,与肌肉流失疾病相关、添加谷氨酰胺的医用食品公开专利只有CN106072573A、CN108497502A、CN109198347A和CN110226756A。CN106072573A提供了一种适用于老年肌肉衰减症的特膳食品,该特膳食品使用山药、大枣、黑芝麻、枸杞子和香菇药食同源药材,同时添加蛋白(包括肽、氨基酸)、脂肪、膳食纤维、β-羟基β-甲基丁酸钙、复合维生素与复合矿物质,所述氨基酸包括亮氨酸、精氨酸、赖氨酸和谷氨酰胺。尽管该特膳食品营养全面,但因添加药食同源药材,且剂型为混合粉剂,存在如上所述的口味差与非无菌缺点。CN108497502A公开了一种中药复合谷氨酰胺特殊膳食食品及其制备方法,适用于促进术后胃肠功能恢复及增加细胞的体积,促进肌肉的生长。该产品除了含谷氨酰胺外,还含有鱼胶原蛋白肽、低聚异麦芽糖与复合中药材(茯苓、莱菔子、山楂等)提取物。该专利产品营养素不全面,添加中药材致口味差,同时还存在非无菌的缺点,使用效果存疑。CN109198347A披露一种大豆肽固体饮料,期望为老年人提供优质蛋白质来源,降低老年人肌肉减少症的发生。该产品除含有大豆肽、谷氨酰胺外,还包含枸杞果粉、阿拉伯糖、柠檬酸、果胶、复合甜味剂与复合维生素。该产品为谷氨酰胺与维生素强化型肽粉。CN110226756A公开了一种预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法。该产品含植物源蛋白和/或植物源蛋白水解物和/或植物源肽类、动物源蛋白和/或动物源蛋白水解物和/或动物源肽类、亮氨酸、异亮氨酸、缬氨酸、谷氨酰胺、精氨酸和蛋氨酸。该专利产品属于特种氨基酸强化型蛋白粉。无论肽粉,还是蛋白粉,虽然强化了谷氨酰胺与支链氨基酸,但营养成分单一,肌肉流失防治效果欠佳。其他添加谷氨酰胺、与肌肉相关的专利,如CN1719984A、CN101248900、CN104522675A、CN106617086A、CN107440126A、CN107772446A和CN108142927A,涉及产品都属运动营养食品,用于缓解肌肉疲劳,增加肌肉力量,增强运动能力。
经检索,同时含有谷氨酰胺与HMBCa、与肌肉相关的专利申请有三项,即CN106072573A、CN107772446A与CN108142927A。CN106072573A即前述使用山药、大枣、黑芝麻、枸杞子和香菇药食同源药材、用于老年肌肉衰减症的特膳食品。CN107772446A与CN108142927A所涉产品同属运动营养食品。由于谷氨酰胺不能耐受高温高压灭菌,高温灭菌的肠外营养产品中,一般使用丙氨酰谷氨酰胺代替谷氨酰胺。目前市场上没有与肌肉有关的丙氨酰谷氨酰胺口服产品销售,也未见相关专利申请。
发明内容
本发明目标是提供一种防止肌肉流失的无菌口服液。该口服液由丙氨酰谷氨酰胺、大豆肽、β-羟基β-甲基丁酸钙、鱼油、磷脂、维生素D2或D3、乳清分离蛋白和水构成。该口服液口味好、服用体积小、适合目标人群长期服用。
技术方案
本发明提供一种防治肌肉流失的口服液。该口服液由丙氨酰谷氨酰胺、大豆肽、β-羟基β-甲基丁酸钙和去离子水构成。
本发明所述口服液,用于肌少症、长期卧床、大手术或创伤人群以及结核、肿瘤等慢性消耗性疾病患者,对肌肉流失有预防和治疗作用。
优选的,本发明所述口服液,每100ml,包含丙氨酰谷氨酰胺5-20g、大豆肽4-8g、β-羟基β-甲基丁酸钙1-3g、去离子水适量。
如前所述,大手术、外伤人群以及癌症患者,体内谷氨酰胺消耗增加,需求量远远大于内源性产生量,需要外源补充才能满足需求。谷氨酰胺还可促进骨骼肌蛋白合成,对肌少症与长期卧床人群有益。本发明所述口服液使用的丙氨酰谷氨酰胺,是由丙氨酸与谷氨酰胺缩合而成的二肽,其生物利用度高,口服吸收后,可在体内迅速分解为谷氨酰胺与丙氨酸,供机体物质合成与能量消耗使用。丙氨酰谷氨酰胺热稳定性好,可耐受高温高压灭菌。
大豆肽水解自大豆分离蛋白。大豆分离蛋白属优质蛋白,其精氨酸含量是乳清蛋白的三倍,BCAA含量高达20%,是补充BCAA的优质原料。精氨酸可促进肌肉的增长,BCAA能阻止肌肉分解,加快肌肉蛋白合成。大豆肽分子量适中,水溶性好,加热不变性,无需消化即可直接吸收,为肌肉蛋白质合成提供原料。
本发明所述口服液使用的β-羟基β-甲基丁酸钙,是HMB的钙盐,与HMB具有相同的功效。卧床不起病人服用HMBCa,可减少肌肉萎缩。临床试验表明,补充HMBCa对一些疾病(如结核、恶性肿瘤)造成的肌肉流失有改善作用;HMBCa还可降低肌少症的发生,延缓老年人肌肉力量的下降。
本发明所述口服液,每100ml,还可以包含,鱼油6-10g、磷脂0.8-1.2g、维生素D2或D315-25μg。
本发明所述口服液中的鱼油,含有DHA、EPA。DHA、EPA属ω-3多不饱和脂肪酸(PUFA),是具有抗炎作用的必需脂肪酸,能降低体内炎症水平,缓解肌肉蛋白合成抵抗。有研究表明,在力量训练中补充鱼油,能显著提高肌力和肌肉蛋白的合成能力。
胆碱是一种有机碱营养素,在维持神经系统的正常功能与脂类代谢中有重要作用。作为甲基供体,胆碱参与肌酸的合成,对肌肉蛋白合成代谢有积极影响。人体所需胆碱的90%由外源性磷脂提供。同时磷脂作为人体细胞膜的重要成分,肩负着细胞内外物质交换的重任,在肌纤维细胞膜损伤修复、肌细胞活化与生长中,发挥重大作用。本发明所述口服液中使用的磷脂,不仅可为目标人群提供胆碱、脂类营养素,同时充当本发明所述口服液的乳化剂。
传统认为,维生素D是影响钙磷代谢、骨骼健康的维生素。近年研究发现,维生素D与肌肉的关系也非常密切。维生素D口服吸收后,首先在肝脏羟化为25-OH D,然后在肾脏转化为活性形式1,25-(OH)2D。进入肌肉细胞后,1,25-(OH)2D与维生素D受体(Vitamin DReceptor,VDR)结合,刺激肌肉细胞增殖和生长。维生素D缺乏,可致肌肉质量减少、力量下降。由于老年人皮肤7-脱氢胆固醇合成减少,肝肾转化活性维生素D功能减弱以及肌肉内VDR表达减少,更容易缺乏维生素D。长期卧床与下肢创伤、手术人群,缺少户外活动,日照不足,也容易缺乏维生素D。补充维生素D能改善肌肉功能、减少跌倒与骨折的风险。此外,维生素D还可降低炎性因子IL-6、TNF-α、hs-CRP水平,升高IL-10,起到抗炎、调节免疫的作用。外伤、手术人群与结核、肿瘤患者,体内普遍存在炎症反应,都有必要补充维生素D。本发明所述口服液中维生素D2与维生素D3均可使用。
本发明所述口服液,还可以包含乳清分离蛋白、乳清浓缩蛋白、蛋清蛋白、乳清蛋白肽、酪蛋白肽,为肌肉蛋白质合成提供原料。
优选的,本发明所述口服液,每100ml,还可以包含,乳清分离蛋白(WPI90)5-10g,。
乳清蛋白是乳清(奶酪生产副产物)的干燥物,根据蛋白质含量不同,乳清蛋白分为乳清浓缩蛋白(WPC,蛋白含量34%-90%)与乳清分离蛋白(WPI,蛋白含量≥90%)。乳清分离蛋白属优质蛋白,富含支链氨基酸,不仅可提供肌肉蛋白质合成所需原料,还可刺激胰岛素合成,增强胰岛素敏感性,促进骨骼肌蛋白合成。此外,乳清分离蛋白易消化吸收,是防治肌肉流失的首选蛋白原料。乳清蛋白与大豆肽联用,优势互补,氨基酸营养更均衡。
本发明所述口服液,可添加维生素C、维生素E、牛磺酸等营养强化剂,其用量参照食品安全国家标准食品营养强化剂使用标准》(GB14880)。
本发明所述口服液,可添加甘油、黄原胶、阿拉伯胶、卡拉胶、海藻酸钠,聚葡萄糖、普鲁兰糖等增稠剂,一方面可增加本发明所述口服液稳定性,另一方面可以防止老年人服用本发明所述口服液时出现的咳呛现象。增稠剂用量参照《食品安全国家标准食品添加剂使用标准》(GB2760)。
本发明所述口服液,可添加低聚木糖、低聚异麦芽糖、低聚果糖、低聚半乳糖、大豆低聚糖等,用于调理肠道功能,改善腹泻与便秘。低聚糖用量参照《食品安全国家标准食品营养强化剂使用标准》(GB14880)。
本发明所述口服液,可使用蔗糖、葡萄糖、果葡糖浆、木糖醇、山梨糖醇、麦芽糖醇、异麦芽酮糖、甘露糖醇、甜菊糖、甘草酸钾、甜蜜素、安赛蜜、三氯蔗糖、阿斯巴甜等甜味剂单独或混合调味。甜味剂用量,参照《食品安全国家标准食品添加剂使用标准》(GB2760)。
本发明所述口服液,可添加食用香精调香,香精用量参照《食品安全国家标准食品添加剂使用标准》(GB2760)。
本发明所属口服液,只使用丙氨酰谷氨酰胺、大豆肽、β-羟基β-甲基丁酸钙三种活性成分时,被制成溶液型口服液,罐装于可耐受高压灭菌的容器后,高压灭菌。
本发明所属口服液,含有丙氨酰谷氨酰胺、大豆肽、β-羟基β-甲基丁酸钙与乳清分离蛋白(WPI90)时,被制成的溶液型口服液,经超高温瞬时灭菌(温度140-145℃,时间10-15秒),无菌罐装于预先灭菌的容器中,密封。
本发明所属口服液,添加鱼油、磷脂、维生素D2或D3后,被制成乳液型口服液。为使产品稳定、均一,制备过程中,使用高压均质机均质,均质压力约为60Mpa。乳剂型口服液不论是否添加乳清分离蛋白(WPI90),均经超高温瞬时灭菌(温度140-145℃,时间10-15秒),无菌灌装至预先的灭菌容器中,密封。
本发明所述口服液用于防治目标人群肌肉流失,用法用量为每日服用两次,每次50ml。
本发明所述口服液口味好、完全无菌、服用体积小、携带方便,适合目标人群长期服用。
有益效果
本发明所述口服液含有丙氨酰谷氨酰胺、大豆肽、β-羟基β-甲基丁酸钙、鱼油、磷脂、维生素D与乳清分离蛋白。丙氨酰谷氨酰胺热稳定性好,可补充衰老与疾病状态下谷氨酰胺的消耗,维护肠道正常功能、增强免疫力,抑制肌肉分解。大豆肽必需氨基酸种类齐全、数量充足、分子量适中,可直接吸收。β-羟基β-甲基丁酸钙,促进肌肉蛋白质合成。鱼油所含必需脂肪酸DHA、EPA,降低炎症反应水平。磷脂是构成肌纤维细胞膜的主要成分,参与细胞膜扩增与损伤修复。维生素D刺激肌肉细胞增殖与生长,乳清分离蛋白是防治肌肉流失的优质原料,与大豆肽立联用,氨基酸营养更均衡。本发明所述口服液营养全面,多种营养素协同作用,共同起到促进肌肉生长,防治肌肉流失的作用。
具体实施方式
实施例1
配方:丙氨酰谷氨酰胺20kg、大豆肽8kg、β-羟基β-甲基丁酸钙3kg、黄原胶100g、三氯蔗糖15g、去离子水69kg;
制法:1.称料,依重量自小至大顺序,称取各原料;
2.溶解增稠剂,取容器,加去离子水10kg,搅拌下,缓慢加入黄原胶,继续搅拌至完全溶解,备用;
3.浓配与过滤,配料罐中加去离子水50kg,搅拌下依次加入三氯蔗糖、β-羟基β-甲基丁酸钙、大豆肽与丙氨酰谷氨酰胺,搅拌至完全溶解;浓配液经0.25μm微孔滤膜过滤;
4.稀配,经过滤的浓配液与增稠剂溶液混合,补去离子水至配方全量;
5.罐装,罐装至50ml旋转口玻璃瓶中,每瓶50ml,使用内衬密封硅胶垫的金属旋转瓶盖,封口;
6.灭菌,115℃,10分钟,高压灭菌;
7.检验,冷却至室温,检验;
8.贴签,包装,得成品。
实施例2
配方:丙氨酰谷氨酰胺17kg、大豆肽8kg、乳清分离蛋白(WPI90)5kg、蔗糖1kg、β-羟基β-甲基丁酸钙1kg、卡拉胶60g、维生素C50g、阿斯巴甜40g、去离子水68kg;
制法:1.容器灭菌,50ml旋转口玻璃瓶与内衬密封硅胶垫金属旋转瓶盖,灭菌,备用;
2.称料,依重量自小至大顺序,称取各原料;
3.溶解增稠剂,取容器,加去离子水10kg,搅拌下,缓慢加入卡拉胶,继续搅拌至完全溶解,备用;
4.浓配与过滤,配料罐中加去离子水50kg,加热至50℃,搅拌下依次加入阿斯巴甜、维生素C、β-羟基β-甲基丁酸钙、蔗糖、乳清分离蛋白(WPI90)、大豆肽与丙氨酰谷氨酰胺,搅拌至完全溶解;浓配液经0.25μm微孔滤膜过滤;
5.稀配,经过滤的浓配液与增稠剂溶液混合,补去离子水至配方全量;
6.灭菌与罐装,药液经超高温瞬时灭菌(温度140-145℃,时间10秒),无菌罐装至预先灭菌的50ml玻璃瓶中,封口;
7.检验,冷却至室温,检验;
8.贴签,包装,即得成品。
实施例3
配方:丙氨酰谷氨酰胺11kg、大豆肽7kg、葡萄糖2kg、β-羟基β-甲基丁酸钙2kg、安赛蜜35g、去离子水67kg;
鱼油10kg、磷脂1.2kg、维生素E 4g、维生素D2 20mg。
制法:1.容器灭菌,50ml旋转口玻璃瓶与内衬密封硅胶垫金属旋转瓶盖,分别灭菌,备用;
2.称料,依重量自小至大顺序,称取各原料;
3.油相混合,加热鱼油至60℃,搅拌下加入维生素E与维生素D2,溶解后加磷脂,搅拌至完全溶解,保温备用;
4.水相配制,配料罐内加去离子水67kg,升温至55℃,搅拌下依次加入安赛蜜、β-羟基β-甲基丁酸钙、葡萄糖、大豆肽与丙氨酰谷氨酰胺,搅拌至完全溶解;
5.乳化与调配,55℃保温水相中,高速(3000rpm)搅拌下,缓慢加入油相,约5分钟加完,继续搅拌10分钟,得初乳;用1M NaOH调pH值至7.5,得乳液;
6.均质,温度50-55℃乳液,使用高压均质机循环处理,均质压力为60Mpa,循环4次,得均质乳液;
7.灭菌与罐装,均质乳液经超高温瞬时灭菌(温度140-145℃,时间13秒),无菌罐装至已灭菌的50ml玻璃瓶中,封口;
8.检验,冷却至室温,检验;
9.贴签、包装,即得成品。
实施例4
配方:乳清分离蛋白(WPI90)10kg、丙氨酰谷氨酰胺8kg、大豆肽4kg、葡萄糖3kg、β-羟基β-甲基丁酸钙2kg、维生素C 50g、甜菊糖30g、去离子水66.2kg;
鱼油6kg、磷脂0.8kg、维生素D3 15mg。
制法:1.容器灭菌,50ml旋转口玻璃瓶与内衬密封硅胶垫金属旋转瓶盖,分别灭菌,备用;
2.称料,依重量自小至大顺序,称取各原料;
3.油相混合,加热鱼油至60℃,搅拌下加入维生素D3,溶解后加磷脂,搅拌至完全溶解,保温备用;
4.水相配制,配料罐内加去离子水66.2kg,升温至55℃,搅拌下依次加入甜菊糖、维生素C、β-羟基β-甲基丁酸钙、葡萄糖、大豆肽、丙氨酰谷氨酰胺,完全溶解后,即得;
5.乳化,55℃保温水相中,高速(3000rpm)搅拌下,缓慢加入油相,约5分钟加完,继续搅拌10分钟,得初乳;
6.乳液调配,初乳55℃保温,用1M NaOH调pH值至7.5,加入乳清分离蛋白(WPI90),搅拌至溶解,得乳液;
7.均质,温度50-55℃乳液,使用高压均质机循环处理,均质压力为60Mpa,循环4次,得均质乳液;
8.灭菌与罐装,均质乳液经超高温瞬时灭菌(温度140-145℃,时间15秒),无菌罐装至已灭菌的50ml玻璃瓶中,封口;
9.检验,冷却至室温,检验;
10.贴签、包装,即得成品。
实施例5
配方:乳清分离蛋白(WPI90)8kg、大豆肽6kg、丙氨酰谷氨酰胺5kg、β-羟基β-甲基丁酸钙3kg、蔗糖2kg、甘草酸钾14g、去离子水67kg;
鱼油8kg、磷脂1.0kg、维生素E 4g、维生素D3 25mg。
制法:1.容器灭菌,50ml旋转口玻璃瓶与内衬密封硅胶垫金属旋转瓶盖,分别灭菌,备用;
2.称料,依重量自小至大顺序,称取各原料;
3.油相混合,加热鱼油至60℃,搅拌下加入维生素E与维生素D3,溶解后加磷脂,搅拌至完全溶解,保温备用;
4.水相配制,配料罐内加去离子水67kg,升温至55℃,搅拌下依次加入甘草酸钾、蔗糖、β-羟基β-甲基丁酸钙、丙氨酰谷氨酰胺与大豆肽,完全溶解后,即得;
5.乳化,55℃保温水相中,高速(3000rpm)搅拌下,缓慢加入油相,约5分钟加完,继续搅拌10分钟,得初乳;
6.乳液调配,初乳55℃保温,用1M NaOH调pH值至7.5,加入乳清分离蛋白(WPI90),搅拌至溶解,得乳液;
7.均质,温度50-55℃乳液,使用高压均质机循环处理,均质压力为60Mpa,循环4次,得均质乳液;
8.灭菌与罐装,均质乳液经超高温瞬时灭菌(温度140-145℃,时间15秒),无菌罐装至已灭菌的50ml玻璃瓶中,封口;
9.检验,冷却至室温,检验;
10.贴签、包装,即得成品。
Claims (3)
1.一种防治肌肉流失的口服液,其特征在于,每100ml含丙氨酰谷氨酰胺5-20g、大豆肽4-8g、β-羟基β-甲基丁酸钙1-3g、去离子水适量。
2.根据权利要求1所述的口服液,其特征在于,每100ml,还可以包含,鱼油6-10g、磷脂0.8-1.2g、维生素D2或D315-25μg。
3.根据权利要求1、2所述的口服液,其特征在于,每100ml,还可以包含,乳清分离蛋白(WPI90)5-10g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911271940.3A CN111035017A (zh) | 2019-12-12 | 2019-12-12 | 一种防治肌肉流失的口服液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911271940.3A CN111035017A (zh) | 2019-12-12 | 2019-12-12 | 一种防治肌肉流失的口服液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111035017A true CN111035017A (zh) | 2020-04-21 |
Family
ID=70236199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911271940.3A Pending CN111035017A (zh) | 2019-12-12 | 2019-12-12 | 一种防治肌肉流失的口服液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111035017A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109198347A (zh) * | 2017-06-30 | 2019-01-15 | 浙江京新生物科技有限公司 | 一种大豆肽固体饮料及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103622121A (zh) * | 2013-11-13 | 2014-03-12 | 精晶药业股份有限公司 | 一种含丙谷二肽的固体饮品 |
CN105327332A (zh) * | 2014-08-09 | 2016-02-17 | 山东国际生物科技园发展有限公司 | 一种丙谷二肽口服片剂及其制备方法 |
CN105360847A (zh) * | 2014-09-01 | 2016-03-02 | 山东国际生物科技园发展有限公司 | 一种丙谷二肽保健饮料及其制备方法 |
CN106072573A (zh) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | 一种适用于老年肌肉衰减症食用的特膳食品 |
CN106307553A (zh) * | 2016-08-11 | 2017-01-11 | 广州白云山汉方现代药业有限公司 | 一种含hmb的大豆肽蛋白质粉及其制备方法 |
CN107772446A (zh) * | 2016-08-26 | 2018-03-09 | 华仁药业股份有限公司 | 一种用于速度力量类的高蛋白营养物组合及其制备方法 |
CN108142927A (zh) * | 2017-12-25 | 2018-06-12 | 诺和生物技术(天津)有限公司 | 一种用于满足运动控制体重需求的组合物及其制备方法 |
CN108618129A (zh) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | 肌肉衰减综合症专用型临床营养配方及其制备方法 |
CN109077302A (zh) * | 2018-07-18 | 2018-12-25 | 辰欣药业股份有限公司 | 一种治疗和预防老年肌肉衰减综合症的医用食品及其制备方法 |
-
2019
- 2019-12-12 CN CN201911271940.3A patent/CN111035017A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103622121A (zh) * | 2013-11-13 | 2014-03-12 | 精晶药业股份有限公司 | 一种含丙谷二肽的固体饮品 |
CN105327332A (zh) * | 2014-08-09 | 2016-02-17 | 山东国际生物科技园发展有限公司 | 一种丙谷二肽口服片剂及其制备方法 |
CN105360847A (zh) * | 2014-09-01 | 2016-03-02 | 山东国际生物科技园发展有限公司 | 一种丙谷二肽保健饮料及其制备方法 |
CN106072573A (zh) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | 一种适用于老年肌肉衰减症食用的特膳食品 |
CN106307553A (zh) * | 2016-08-11 | 2017-01-11 | 广州白云山汉方现代药业有限公司 | 一种含hmb的大豆肽蛋白质粉及其制备方法 |
CN107772446A (zh) * | 2016-08-26 | 2018-03-09 | 华仁药业股份有限公司 | 一种用于速度力量类的高蛋白营养物组合及其制备方法 |
CN108142927A (zh) * | 2017-12-25 | 2018-06-12 | 诺和生物技术(天津)有限公司 | 一种用于满足运动控制体重需求的组合物及其制备方法 |
CN108618129A (zh) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | 肌肉衰减综合症专用型临床营养配方及其制备方法 |
CN109077302A (zh) * | 2018-07-18 | 2018-12-25 | 辰欣药业股份有限公司 | 一种治疗和预防老年肌肉衰减综合症的医用食品及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109198347A (zh) * | 2017-06-30 | 2019-01-15 | 浙江京新生物科技有限公司 | 一种大豆肽固体饮料及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6368617B1 (en) | Dietary supplement | |
JP5830030B2 (ja) | 筋タンパク質合成を刺激するための低カロリー高タンパク質栄養組成物 | |
CN109222103B (zh) | 增肌组合物和保健食品 | |
CN111616232A (zh) | 一种促进骨骼生长的儿童奶粉及其制备方法 | |
CN103783532B (zh) | 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法 | |
US9950024B2 (en) | Traditional Chinese medicine composition and the use thereof | |
EP1176880A1 (en) | Supplement for restoring growth hormone levels | |
CN112772813A (zh) | 一种提高免疫力缓解疲劳的复合肽固体饮料及其制备方法 | |
CN104855994A (zh) | 肾病非全营养配方食品 | |
TWI830696B (zh) | 抑制肌纖維變性用組成物 | |
CN104855997A (zh) | 骨质疏松非全营养配方食品 | |
CN113632851A (zh) | 一种多功能儿童生长奶粉及其制备方法 | |
CN111771988A (zh) | 适用于糖尿病人食用的营养食品及其制备方法 | |
CN111296585A (zh) | 一种促进儿童身高增长和大脑发育的配方奶粉及制备方法 | |
CN110214942A (zh) | 一种甲亢专用型医学营养配方及其制备方法 | |
CN107467193B (zh) | 一种以羊奶为基础的粉剂全营养特殊医学用途配方食品及其制备方法 | |
CN1101700C (zh) | 多肽口服液 | |
WO2022165700A1 (zh) | 一种多肽营养粉及其制备方法 | |
CN111035017A (zh) | 一种防治肌肉流失的口服液 | |
CN115969961A (zh) | 改善骨密度的钙、vd、蛋白肽组合物及其制备方法和应用 | |
CN104839704A (zh) | 壮阳非全营养配方食品 | |
CN112472733B (zh) | 一种促进钙口服吸收的葛花提取物 | |
CN104839671A (zh) | 壮阳医学配方食品 | |
CN108095075A (zh) | 流产女性专用型临床营养配方及其制备方法 | |
TWI745667B (zh) | 一種大豆分離蛋白用於製備預防或治療骨鬆合併肌少症、提升身體機能及降低運動後疲勞之組合物的用途。 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200421 |